With biotech sentiment improving, IOVA stock forecast data points to a 15% upside potential if regulatory timelines hold. RSI readings near 58 suggest moderate buying pressure without overextension risk. To put it simply, this stock's poor performance since 2021 is mainly due to its exceptional performance in 2019 and 2020. That's when Amtagvi's potential approval first began to firm up, particularly in light of the FDA's willingness to designate it as a breakthrough therapy for cervical cancer. This designation accelerates a drug's regulatory review process when the agency feels a new, better treatment option is needed. It's also an unspoken vote of confidence in the therapy's underlying T-cell science. Written by Quiver PriceTracker for Quiver Quantitative -> IOVA stock forecast modeling shows beta at 1.52, suggesting heightened sensitivity to market shifts. Short interest stands at 8%, a slight decrease after recent positive trial news.
